Receptos Company Profile (NASDAQ:RCPT)

About Receptos

Receptos logoReceptos, Inc. (Receptos) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing therapeutics in immune disorders. Its product candidates span three disease areas. It is developing its lead asset, ozanimod (formerly RPC1063), as an oral therapy for the treatment of Relapsing Multiple Sclerosis (RMS) and Inflammatory Bowel Disease (IBD), which consists of Ulcerative Colitis (UC) and Crohn's Disease (CD). It is developing its second asset, RPC4046, for the treatment of an allergic/immune-mediated disorder, Eosinophilic Esophagitis (EoE), for which it has been granted Orphan drug designation. Its research efforts include a preclinical program developing oral, small molecule, positive allosteric modulators (PAMs) of the glucagon-like peptide-1 receptor (GLP-1R) for the treatment of Type 2 Diabetes.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: RCPT
  • CUSIP:
Key Metrics:
  • Previous Close: $231.96
  • 50 Day Moving Average: $226.05
  • 200 Day Moving Average: $174.22
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -28.25
  • P/E Growth: 0.00
  • Market Cap: $N/A
Additional Links:
Companies Related to Receptos:

Analyst Ratings

Consensus Ratings for Receptos (NASDAQ:RCPT) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Receptos (NASDAQ:RCPT)
DateFirmActionRatingPrice TargetDetails
8/26/2015WedbushDowngradeOutperform -> Neutral$232.00View Rating Details
7/17/2015Evercore Partners Inc.Reiterated RatingBuy -> HoldView Rating Details
7/17/2015Evercore ISIDowngradeBuy -> HoldView Rating Details
7/15/2015NomuraDowngradeBuy -> Neutral$202.00 -> $232.00View Rating Details
7/15/2015BMO Capital MarketsDowngradeOutperform -> Market Perform$232.00View Rating Details
2/19/2015Credit Suisse GroupBoost Price TargetOutperform$125.00 -> $140.00View Rating Details
(Data available from 2/19/2015 forward)


Earnings History for Receptos (NASDAQ:RCPT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/5/2015Q115($1.09)($1.29)$5.10 millionViewN/AView Earnings Details
3/3/2015Q414($1.19)($1.32)ViewN/AView Earnings Details
11/4/2014Q314($0.96)($1.19)$3.50 millionViewN/AView Earnings Details
8/12/2014Q214($0.85)($1.04)$1.28 million$1.10 millionViewN/AView Earnings Details
5/12/2014Q114($0.84)($1.01)$0.49 million$1.40 millionViewN/AView Earnings Details
3/5/2014($0.86)($0.86)ViewN/AView Earnings Details
10/30/2013Q313($0.61)($0.88)$1.10 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Receptos (NASDAQ:RCPT)
Current Year EPS Consensus Estimate: $-7.14 EPS
Next Year EPS Consensus Estimate: $-8.21 EPS


Dividend History for Receptos (NASDAQ:RCPT)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Receptos (NASDAQ:RCPT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/16/2015S. Edward TorresDirectorSell220,000$178.99$39,377,800.00View SEC Filing  
2/23/2015S. Edward TorresDirectorSell47,906$128.20$6,141,549.20View SEC Filing  
11/11/2014Faheem HasnainCEOSell200,000$109.47$21,894,000.00View SEC Filing  
11/11/2014Sheila GujrathiInsiderSell30,000$108.99$3,269,700.00View SEC Filing  
11/10/2014Chrysa MineoSVPSell30,000$109.73$3,291,900.00View SEC Filing  
11/10/2014Faheem HasnainCEOSell136,795$109.69$15,005,043.55View SEC Filing  
11/10/2014Marcus F BoehmCTOSell40,454$109.91$4,446,299.14View SEC Filing  
9/23/2014S. Edward TorresDirectorSell100,000$61.36$6,136,000.00View SEC Filing  
9/22/2014S. Edward TorresDirectorSell14,318$63.08$903,179.44View SEC Filing  
9/22/2014Sheila GujrathiInsiderSell30,000$61.45$1,843,500.00View SEC Filing  
9/19/2014S. Edward TorresDirectorSell169,570$62.55$10,606,603.50View SEC Filing  
9/18/2014S. Edward TorresDirectorSell91,513$62.77$5,744,271.01View SEC Filing  
9/17/2014David A HinkleCAOSell2,000$64.82$129,640.00View SEC Filing  
9/17/2014S. Edward TorresDirectorSell38,917$63.67$2,477,845.39View SEC Filing  
9/16/2014Graham K CooperCFOSell50,000$61.30$3,065,000.00View SEC Filing  
9/2/2014David A HinkleCAOSell2,000$52.80$105,600.00View SEC Filing  
8/13/2014David A HinkleCAOSell3,000$42.69$128,070.00View SEC Filing  
8/13/2014S. Edward TorresDirectorSell200,000$43.24$8,648,000.00View SEC Filing  
5/29/2014Kristina BurowDirectorSell153,698$29.74$4,570,978.52View SEC Filing  
5/21/2014S. Edward TorresDirectorSell424,068$25.26$10,711,957.68View SEC Filing  
5/15/2014S. Edward TorresDirectorSell90,075$27.37$2,465,352.75View SEC Filing  
5/14/2014Kristina BurowDirectorSell45,381$29.66$1,346,000.46View SEC Filing  
1/3/2014William RastetterDirectorSell37,359$30.85$1,152,525.15View SEC Filing  
1/2/2014William RastetterDirectorSell27,581$30.29$835,428.49View SEC Filing  
12/6/2013Amir NashatDirectorSell170,000$26.70$4,539,000.00View SEC Filing  
12/5/2013William RastetterDirectorSell500,000$27.63$13,815,000.00View SEC Filing  
11/18/2013Ventures Fund 2007 Flagshipmajor shareholderSell230,787$24.75$5,711,978.25View SEC Filing  
11/15/2013Amir NashatDirectorSell169,315$24.96$4,226,102.40View SEC Filing  
5/14/2013Amir NashatDirectorBuy151,343$14.00$2,118,802.00View SEC Filing  
5/14/2013Ventures Fund 2007 L FlagshipMajor ShareholderBuy107,142$14.00$1,499,988.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Receptos (NASDAQ:RCPT)
News IconEarnings at a Glance For Receptos, Inc. (NASDAQ:RCPT): What Are Analysts Predicting For the Stock? - Winfield Review (NASDAQ:RCPT) - February 18 at 8:13 AM
News IconEarnings Snapshot & Analysts Target Update on Receptos, Inc. (NASDAQ:RCPT)? - Wall Street Beacon (NASDAQ:RCPT) - February 1 at 6:39 AM
News IconIs There Inherent Value in Receptos, Inc. (NASDAQ:RCPT)? Analysts Delve Into The Stock - Wall Street Beacon (NASDAQ:RCPT) - January 30 at 8:06 AM
News IconReceptos, Inc. (NASDAQ:RCPT) Under Analyst Spotlight - UK Market News (NASDAQ:RCPT) - January 29 at 12:37 AM
News IconAnalysts Pounding The Pavement on Receptos, Inc. (NASDAQ:RCPT): Consensus Update - Wall Street Beacon (NASDAQ:RCPT) - January 24 at 8:15 AM
News IconReceptos Inc RCPT Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:RCPT) - January 22 at 7:13 PM
News IconEarnings Fever Sweeping In, What Are Analysts Expecting From Receptos, Inc. (NASDAQ:RCPT)? - Wall Street Beacon (NASDAQ:RCPT) - January 18 at 12:51 AM
News IconWall Street and Armchair Analysts Weigh in on Receptos, Inc. (NASDAQ:RCPT) Heading Into The New Year - Wall Street Beacon (NASDAQ:RCPT) - January 13 at 1:11 AM logoInsider Selling Picks Up as Market Volatility Jumps (NASDAQ:RCPT) - January 9 at 7:27 AM logoBiotech Bull Markets and Billion-Dollar Valuations (NASDAQ:RCPT) - January 9 at 7:27 AM logoReceptos Inc (RCPT), Centene Corp (CNC): Paul Sinclair Flying High With New Fund’s Top Healthcare Picks (NASDAQ:RCPT) - January 9 at 7:27 AM logoReceptos Inc (RCPT) Up On Bullish Takeover Report: Is It A Buy Now? (NASDAQ:RCPT) - January 9 at 7:27 AM logoHuge Biotech Trade Highlights Insider Selling as Market Hits Record Highs (NASDAQ:RCPT) - January 9 at 7:27 AM logoCelgene to buy Receptos for $7.2 bln (NASDAQ:RCPT) - January 9 at 7:27 AM logoCelgene to buy Receptos for $7.2 billion (NASDAQ:RCPT) - January 9 at 7:27 AM logoCelgene will buy drug developer Receptos for $7.32 billion (NASDAQ:RCPT) - January 9 at 7:27 AM logoCelgene to buy Receptos for $7.2 bln; gains promising drug (NASDAQ:RCPT) - January 9 at 7:27 AM logoHedge Fund Were Wrong About Receptos Inc (RCPT) As Celgene Corporation (CELG) Snatches It Up At Premium (NASDAQ:RCPT) - January 9 at 7:27 AM logoIs Celgene Transforming Itself With Mergers and Pacts? (NASDAQ:RCPT) - January 9 at 7:27 AM logoWall Street lauds Celgene's $7.2 billion Receptos buy (NASDAQ:RCPT) - January 9 at 7:27 AM logoBioniz Therapeutics Appoints Paul Frohna M.D., Ph.D., Pharm. D., as Senior Vice President of Clinical Development (NASDAQ:RCPT) - December 20 at 7:10 PM
News IconVital Therapies Announces Third Quarter Financial Results (NASDAQ:RCPT) - November 3 at 7:05 PM
News IconNew Analyst Ratings On Receptos, Inc. (NASDAQ:RCPT) - NewsDen (NASDAQ:RCPT) - October 21 at 10:32 AM logoStocks Gapping Up Today – KELYB, CERU, LOAN, CHKE, MEIP, CBK, ATEA - (NASDAQ:RCPT) - June 13 at 10:01 AM
News IconReceptos, Inc. (NASDAQ:RCPT) Company Earnings in Focus - Stock Caller (NASDAQ:RCPT) - April 18 at 10:36 PM
News IconSentiment Score Review :Receptos, Inc. (NASDAQ:RCPT) - Business Standard Tribune (NASDAQ:RCPT) - April 18 at 10:36 PM
News IconStock Review for: Receptos, Inc. (NASDAQ:RCPT) - Stock Caller (NASDAQ:RCPT) - April 16 at 8:01 PM
News IconTarget Price Check on Receptos, Inc. (NASDAQ:RCPT) - Business Standard Tribune (NASDAQ:RCPT) - April 16 at 8:01 PM
News IconReceptos, Inc. (NASDAQ:RCPT) Focus on Company Earnings - Stock Caller (NASDAQ:RCPT) - April 15 at 10:01 PM
News IconCheck on Impact Score :Receptos, Inc. (NASDAQ:RCPT) - Business Standard Tribune (NASDAQ:RCPT) - April 15 at 10:01 PM logoIs This a Potential $7 Billion Waste for Celgene Corporation? (NASDAQ:RCPT) - January 8 at 8:19 AM logoRECEPTOS, INC. Files SEC form 10-Q, Quarterly Report (NASDAQ:RCPT) - July 30 at 6:12 AM logoMorgan Stanley Raises Price Target On Celgene, Still Highlights Several Risks (NASDAQ:RCPT) - July 27 at 12:24 PM


What is Receptos' stock symbol?

Receptos trades on the NASDAQ under the ticker symbol "RCPT."

When will Receptos announce their earnings?

Receptos is scheduled to release their next quarterly earnings announcement on Wednesday, August, 12th 2015.

How do I buy Receptos stock?

Shares of Receptos can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Receptos stock cost?

One share of Receptos stock can currently be purchased for approximately $231.96.

Receptos (NASDAQ:RCPT) Chart for Sunday, February, 19, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for Receptos (NASDAQ:RCPT)

Earnings History Chart

Earnings by Quarter for Receptos (NASDAQ:RCPT)

Dividend History Chart

Dividend Payments by Quarter for Receptos (NASDAQ:RCPT)

Last Updated on 2/19/2017 by Staff